Home › Compare › INFI vs DVY

INFI vs DVY: Dividend Comparison 2026

INFI yields 25000.00% · DVY yields 3.50%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INFI wins by $481652020747103174656.00M in total portfolio value
10 years
INFI
INFI
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full INFI calculator →
DVY
DVY
● Live price
3.50%
Share price
$150.03
Annual div
$5.25
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$437.78
Full DVY calculator →

Portfolio growth — INFI vs DVY

📍 INFI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINFIDVY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INFI + DVY cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
INFI pays
DVY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFI
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
DVY
Annual income on $10K today (after 15% tax)
$297.17/yr
After 10yr DRIP, annual income (after tax)
$372.11/yr
At 15% tax rate, INFI beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFI + DVY for your $10,000?

INFI: 50%DVY: 50%
100% DVY50/50100% INFI
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on INFI right now

INFI
Analyst Ratings
8
Buy
9
Hold
Consensus: Hold
Altman Z
-63.6
Piotroski
3/9
DVY
No analyst data
Altman Z
307.5
Piotroski
1/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFI buys
0
DVY buys
0
No recent congressional trades found for INFI or DVY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINFIDVY
Forward yield25000.00% ✓3.50%
Annual dividend / share$2.00$5.25 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$481652020747103174656.00M ✓$25.1K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00 ✓$437.78
Total dividends collected$481404327977371041792.00M ✓$4.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: INFI vs DVY ($10,000, DRIP)

YearINFI PortfolioINFI Income/yrDVY PortfolioDVY Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,050$349.62+$2.50M → INFI
2$589,298,599$586,612,149.53$12,184$361.04+$589.29M → INFI
3$129,309,604,119$128,679,054,618.90$13,409$372.07+$129309.59M → INFI
4$26,527,150,102,459$26,388,788,826,051.22$14,730$382.68+$26527150.09M → INFI
5$5,087,743,001,217,608$5,059,358,950,607,977.00$16,154$392.89+$5087743001.20M → INFI
6$912,316,496,169,531,500$906,872,611,158,228,600.00$17,688$402.69+$912316496169.51M → INFI
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$19,338$412.07+$152954929371424.91M → INFI
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$21,113$421.04+$23976822470935108.00M → INFI
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$23,020$429.61+$3514337444199857664.00M → INFI
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$25,070$437.78+$481652020747103174656.00M → INFI

INFI vs DVY: Complete Analysis 2026

INFI — Stock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Full INFI Calculator →

DVY — ETF

The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full DVY Calculator →
📬

Get this INFI vs DVY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFI vs SCHDINFI vs JEPIINFI vs OINFI vs KOINFI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.